Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - influensavacciner - profylax av influensa orsakad av a (h1n1v) 2009 virus. focetria bör användas i enlighet med officiella riktlinjer.

Europeiska unionen - svenska - EMA (European Medicines Agency)

seqirus s.r.l.  - influensavirus-ytantigener (hemagglutinin och neuraminidas) av stam: a / turkiet / turkiet / 1/05 (h5n1) -liknande stam (nibrg-23) - influenza, human; immunization; disease outbreaks - vacciner - aktiv immunisering mot h5n1-subtyp av influensa-a-virus. denna indikation baseras på immunogenicitet data från friska individer från 18 år och framåt efter administrering av två doser av vaccinet som innehåller en/turkiet/turkey/1/05 (h5n1)-liknande stam. aflunov bör användas i enlighet med officiella rekommendationer.

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influensavirusytantigener (hemagglutinin och neuraminidas) av stam a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vacciner - aktiv immunisering mot h5n1-subtyp av influensa a-virus. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Europeiska unionen - svenska - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vacciner - active immunisation against h5 subtype of influenza a virus.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sandoz a/s - vankomycinhydroklorid - pulver till infusionsvätska, lösning - 1000 mg - vankomycinhydroklorid aktiv substans - vankomycin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sandoz a/s - vankomycinhydroklorid - pulver till infusionsvätska, lösning - 500 mg - vankomycinhydroklorid aktiv substans - vankomycin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

viatris limited - vankomycinhydroklorid - pulver till infusionsvätska, lösning - 1000 mg - vankomycinhydroklorid 1025 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

viatris limited - vankomycinhydroklorid - pulver till infusionsvätska, lösning - 500 mg - vankomycinhydroklorid 512,76 mg aktiv substans

Europeiska unionen - svenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

elanco animal health a/s/eli lilly danmark a/s - kattcalicivirus, stam f9, levande försvagat; kattpestvirus, stam snow leopard, levande försvagat; kattsnuvevirus, stam fvrm, levande försvagat - pulver och vätska till injektionsvätska, suspension - kattsnuvevirus, stam fvrm, levande försvagat 5 log10 ccid50 aktiv substans; laktos (vattenfri) hjälpämne; kattpestvirus, stam snow leopard, levande försvagat 3 log10 ccid50 aktiv substans; kattcalicivirus, stam f9, levande försvagat 5,5 log10 ccid50 aktiv substans - felint panleukopenivirus/parvovirus + felint rhinotrakeitvirus (kattsnuva) + felint calicivirus - katt